Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report-Reference-Cited by-同舟云学术

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report

Published:2012-09-03 Issue:5 Volume:27 Page:1174-1177
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Goldman S,Smith L,Anderson J R,Perkins S,Harrison L,Geyer M B,Gross T G,Weinstein H,Bergeron S,Shiramizu B,Sanger W,Barth M,Zhi J,Cairo M S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2012255.pdf

Reference13 articles.

1. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010; 28: 3115–3121.

2. Murphy SB . Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332–339.

3. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773–2780.

4. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736–2743.

5. Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L et al. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol 2011; 153: 758–763.

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults;Journal of the National Comprehensive Cancer Network;2024-07

2. Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors;Expert Review of Hematology;2024-06-25

3. Effects of Different Doses of Rituximab on Immunoglobulin Levels in High-risk Pediatrics with Burkitt’s Lymphoma;2024-05-08

4. BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt/β-catenin signaling;Heliyon;2024-03

5. Effect of rituximab on immune status in children with aggressive mature B-cell lymphoma/leukemia–a prospective study from CCCG-BNHL-2015;Heliyon;2024-03